Five studies presented data about TACC3 expression was significantly associated with TNM stage (III-IV versus I-II OR=1.66, 95% CI=1.25-2.20, P=0.000, I2 =74.5%, Ph = 0.004), a pooled OR of 1.68 indicated a close relationship between increased TACC3 expression and lymph node metastases (N1/N2/N3 versus N0 OR =1.68, 95% CI=1.26–2.25, P=0.000, I2=55.5%, Ph=0.061). This evidence concerns the gene TACC3 and metastatic malignant neoplasm in the lymph nodes.